Could a tiny HPV shot still protect? new study tests smaller doses
NCT ID NCT04235257
First seen May 29, 2026 · Last updated Jun 16, 2026 · Updated 8 times
Summary
This study looks at whether a smaller, skin-deep dose of the HPV vaccine can trigger a strong immune response in adults aged 27 to 45. About 40 participants will receive either a bivalent or nonavalent HPV vaccine as a single fractional injection. Researchers will measure antibody levels over two years to see if the lower dose is effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Washington Virology Research Clinic
Seattle, Washington, 98104, United States
Conditions
Explore the condition pages connected to this study.